544 results on '"Villalona-Calero, Miguel"'
Search Results
152. Clinical and Metabolic Parameters in Non-Small Cell Lung Carcinoma and Colorectal Cancer Patients with and without KRAS Mutations
153. FANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3–FOXO1 Fusion Gene
154. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).
155. Enhancement of cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) with lenalidomide in advanced solid tumors: A phase 1 trial.
156. Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC).
157. Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors
158. Cellular Localization of Protein Arginine Methyltransferase-5 Correlates With Grade of Pulmonary Neuroendocrine Tumors
159. Disrupting Cytokine Signaling in Pancreatic Cancer
160. Case of Sorafenib-Induced Thyroid Storm
161. NCI 8609: Interim fluoro-3’-deoxythymidine (FLT) PET imaging findings from the phase I trial of PARP inhibitor veliparib (V) and carboplatin (C) in advanced breast cancer.
162. Abstract 4365: Sensitivity of small cell lung cancer cells with defective Fanconi Anemia (FA) pathway to BCL2 inhibitors..
163. Abstract LB-139: Phase I trial of veliparib or mitomycin (MMC) + veliparib in patients with sporadic solid tumors screened for somatic deficiency in the Fanconi Anemia (FA) pathway.
164. Abstract 4246: Promoter hypermethylation and gene expression of FANCF in non-small cell lung cancer (NSCLC).
165. Abstract 4221: Mutations in Rad51C in colon tumors.
166. A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC)
167. Inhibition of Ras–effector interactions by cyclic peptides
168. Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.
169. Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.
170. RET Fusion Genes in Non–Small-Cell Lung Cancer
171. In Vivo Quantification of Active Decitabine-Triphosphate Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia
172. Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)
173. Abstract A43: EGFR-targeted therapy in African Americans with advanced non-small cell lung cancer: A prospective clinical, pharmacogenetic, and pharmacokinetic study.
174. Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial
175. Randomized trial of oral cyclophosphamide (C) with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma.
176. Abstract 5586: Phase I study of PARP inhibitor ABT-888 and carboplatin with novel imaging in metastatic breast cancer (MBC) (NCI-8609)
177. Abstract LB-225: Phase 2 Trial ofnab-paclitaxel plus carboplatin for advanced NSCLC in patients at risk of bleeding from VEGF directed therapies
178. Abstract 4740: Establishment of P53 mutant type specific spontaneous lung tumor in transgenic mice for treatment
179. HER2/neu May Not Be an Interesting Target in Biliary Cancers: Results of an Early Phase II Study with Lapatinib
180. Abstract A99: Phase I trial of veliparib or mitomycin C + veliparib in pts with Fanconi anemia pathway (FA) repair defects.
181. Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003)
182. Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors
183. A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors
184. Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
185. Abstract 610: Regression of spontaneous non-small cell lung cancers in P53 mutant transgenic mice following exposure to PRIMA-1
186. Abstract 5500: Inhibition of poly(ADP-ribose) polymerase in lung cancer cells with defective Fanconi anemia (FA) pathway
187. Preoperative Bevacizumab in Combination With Paclitaxel and Carboplatin in Surgically Resectable Non-Small Cell Lung Cancer
188. The search for an optimal DNA, RNA, and protein detection by in situ hybridization, immunohistochemistry, and solution-based methods
189. Risk Factors for Tumor Lysis Syndrome (TLS) In Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol.
190. Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia
191. Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
192. Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma
193. Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung Cancer
194. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
195. Abstract 2594: Reovirus replication in ovarian and peritoneal tumors after intravenous administration
196. Abstract 3750: Functional analysis of the Fanconi Anemia pathway in primary lung tumors
197. Malignant Thymoma With Immunodeficiency (Good Syndrome) Associated With Mucormycosis
198. Abstract B237: Clinical experience of IMGN901 (BB‐10901, huN901‐DM1) in patients with Merkel cell carcinoma (MCC)
199. Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
200. Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.